In vitro and in vivo tests of a nanoplatform combining astaxanthin, SS‑31 and a photoacoustic contrast polymer confirmed anti-atherosclerotic capability.
In plain wordsTests of a nanoparticle that carries astaxanthin, SS‑31 and a contrast agent showed an effect against atherosclerosis. SS‑31 alone was not tested.
- Peptide
- Elamipretide (SS-31)
- Outcome
- DecreaseAnti-atherosclerotic capability
- Study
n: not reported in source
- Outcome group
- Cardiovascular events · Cardiovascular
Source sentences
Both in vitro and in vivo evaluations confirm the impressive anti-atherosclerotic capability and the accurate photoacoustic diagnosis of PA/ASePSD nanoparticles, thus promising a candidate for early-stage atherosclerosis theranostics.
1 context sentence(design, population, supporting numbers)
On this basis, an intelligent responsive theranostic nanoplatform (PA/ASePSD) combining astaxanthin and SS-31 peptide and loading with PMeTPP-MBT is developed.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).